Familial relative risks for lymphoid malignancies and all hematological malignancy, stratified by the age at diagnosis
| . | Age groups, y* . | N . | SIR (95% CI) . | P . |
|---|---|---|---|---|
| All hematological malignancies | ≤56 | 2070 | 1.38 (1.32-1.44) | .05 |
| >56 | 4150 | 1.31 (1.27-1.35) | ||
| ALL | ≤5 | 6 | 2.51 (0.60-5.66) | .69 |
| >5 | 8 | 0.36 (0.01-2.03) | ||
| HL | ≤28 | 45 | 5.76 (4.20-7.70) | 7.3 × 10−3 |
| >28 | 61 | 3.36 (2.57-4.32) | ||
| Nodular sclerosis HL | ≤22 | 6 | 14.29 (5.24-31.09) | .29 |
| >22 | 10 | 8.20 (3.93-15.07) | ||
| NHL | ≤57 | 392 | 1.76 (1.59-1.95) | .89 |
| >57 | 792 | 1.75 (1.63-1.87) | ||
| DLBCL | ≤59 | 18 | 2.65 (1.57-4.18) | .44 |
| >59 | 30 | 2.10 (1.42-3.00) | ||
| FL | ≤56 | 6 | 2.02 (0.74-4.40) | .78 |
| >56 | 12 | 1.76 (0.91-3.07) | ||
| LPL | ≤65 | 8 | 19.05 (8.22-37.53) | .53 |
| >65 | 8 | 13.79 (5.95-27.18) | ||
| MCL | ≤63 | 3 | 13.64 (2.81-39.85) | .93 |
| >63 | 5 | 13.16 (4.27-30.71) | ||
| CLL | ≤63 | 148 | 6.99 (5.91-8.21) | 1.1 × 10−3 |
| >63 | 169 | 4.83 (4.13-5.62) | ||
| MM | ≤63 | 92 | 2.24 (1.81-2.75) | .52 |
| >63 | 136 | 1.96 (1.72-2.43) | ||
| Myeloid malignancies | ≤56 | 167 | 2.19 (1.87-2.55) | .13 |
| >56 | 312 | 1.89 (1.69-2.11) | ||
| MPN | ≤59 | 80 | 6.46 (5.12-8.04) | 4.0 × 10−3 |
| >59 | 101 | 4.15 (3.38-5.04) | ||
| PV | ≤59 | 26 | 10.90 (7.12-15.97) | .03 |
| >59 | 27 | 5.96 (3.93-8.67) | ||
| ET | ≤56 | 10 | 9.76 (4.68-17.95) | .17 |
| >56 | 12 | 5.37 (2.77-9.38) | ||
| CML | ≤47 | 2 | 1.33 (0.16-4.80) | .39 |
| >47 | 2 | 0.55 (0.07-1.99) | ||
| MDS | ≤68 | 13 | 11.95 (6.36-20.43) | 8.8 × 10−3 |
| >68 | 5 | 3.27 (1.06-7.63) | ||
| AML | ≤52 | 13 | 1.48 (0.79-2.53) | .90 |
| >52 | 33 | 1.55 (1.07-2.18) |
| . | Age groups, y* . | N . | SIR (95% CI) . | P . |
|---|---|---|---|---|
| All hematological malignancies | ≤56 | 2070 | 1.38 (1.32-1.44) | .05 |
| >56 | 4150 | 1.31 (1.27-1.35) | ||
| ALL | ≤5 | 6 | 2.51 (0.60-5.66) | .69 |
| >5 | 8 | 0.36 (0.01-2.03) | ||
| HL | ≤28 | 45 | 5.76 (4.20-7.70) | 7.3 × 10−3 |
| >28 | 61 | 3.36 (2.57-4.32) | ||
| Nodular sclerosis HL | ≤22 | 6 | 14.29 (5.24-31.09) | .29 |
| >22 | 10 | 8.20 (3.93-15.07) | ||
| NHL | ≤57 | 392 | 1.76 (1.59-1.95) | .89 |
| >57 | 792 | 1.75 (1.63-1.87) | ||
| DLBCL | ≤59 | 18 | 2.65 (1.57-4.18) | .44 |
| >59 | 30 | 2.10 (1.42-3.00) | ||
| FL | ≤56 | 6 | 2.02 (0.74-4.40) | .78 |
| >56 | 12 | 1.76 (0.91-3.07) | ||
| LPL | ≤65 | 8 | 19.05 (8.22-37.53) | .53 |
| >65 | 8 | 13.79 (5.95-27.18) | ||
| MCL | ≤63 | 3 | 13.64 (2.81-39.85) | .93 |
| >63 | 5 | 13.16 (4.27-30.71) | ||
| CLL | ≤63 | 148 | 6.99 (5.91-8.21) | 1.1 × 10−3 |
| >63 | 169 | 4.83 (4.13-5.62) | ||
| MM | ≤63 | 92 | 2.24 (1.81-2.75) | .52 |
| >63 | 136 | 1.96 (1.72-2.43) | ||
| Myeloid malignancies | ≤56 | 167 | 2.19 (1.87-2.55) | .13 |
| >56 | 312 | 1.89 (1.69-2.11) | ||
| MPN | ≤59 | 80 | 6.46 (5.12-8.04) | 4.0 × 10−3 |
| >59 | 101 | 4.15 (3.38-5.04) | ||
| PV | ≤59 | 26 | 10.90 (7.12-15.97) | .03 |
| >59 | 27 | 5.96 (3.93-8.67) | ||
| ET | ≤56 | 10 | 9.76 (4.68-17.95) | .17 |
| >56 | 12 | 5.37 (2.77-9.38) | ||
| CML | ≤47 | 2 | 1.33 (0.16-4.80) | .39 |
| >47 | 2 | 0.55 (0.07-1.99) | ||
| MDS | ≤68 | 13 | 11.95 (6.36-20.43) | 8.8 × 10−3 |
| >68 | 5 | 3.27 (1.06-7.63) | ||
| AML | ≤52 | 13 | 1.48 (0.79-2.53) | .90 |
| >52 | 33 | 1.55 (1.07-2.18) |
Age group is defined by the lower quartile of the distribution of the diagnosis. P represents a trend test. The age stratification was based on the first quartile of the age at diagnosis distribution of all incident cases for each hematological malignancy. Where a first-degree relative appears in both age groups as a result of being related to 2 or more incident cases, the first-degree relative is counted in the younger age group. Data on the clonal myeloid neoplasms have previously been reported.18
N, number of cases.